During the last session, Aquestive Therapeutics Inc (NASDAQ:AQST)’s traded shares were 0.89 million, with the beta value of the company hitting 2.68. At the end of the trading day, the stock’s price was $3.58, reflecting an intraday loss of -2.45% or -$0.09. The 52-week high for the AQST share is $6.23, that puts it down -74.02 from that peak though still a striking 44.69% gain since the share price plummeted to a 52-week low of $1.98. The company’s market capitalization is $326.41M, and the average intraday trading volume over the past 10 days was 1.35 million shares, and the average trade volume was 1.48 million shares over the past three months.
Aquestive Therapeutics Inc (AQST) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.11. AQST has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.13.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Aquestive Therapeutics Inc (AQST) registered a -2.45% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.45% in intraday trading to $3.58, hitting a weekly high. The stock’s 5-day price performance is -2.19%, and it has moved by -18.45% in 30 days. Based on these gigs, the overall price performance for the year is 71.29%. The short interest in Aquestive Therapeutics Inc (NASDAQ:AQST) is 9.65 million shares and it means that shorts have 6.35 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 64.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $10 respectively. As a result, AQST is trading at a discount of -179.33% off the target high and -179.33% off the low.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Statistics show that Aquestive Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Aquestive Therapeutics Inc (AQST) shares have gone up 44.35% during the last six months, with a year-to-date growth rate less than the industry average at -253.85% against 16.60. In the rating firms’ projections, revenue will increase 13.67% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 13.11M as predicted by 9 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 12.9M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 13.21M and 12.05M respectively. In this case, analysts expect current quarter sales to shrink by -0.71% and then jump by 7.03% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.61%. While earnings are projected to return -235.90% in 2025.
AQST Dividends
Aquestive Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
Aquestive Therapeutics Inc insiders own 5.01% of total outstanding shares while institutional holders control 55.98%, with the float percentage being 58.94%. BRATTON CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 151.0 institutions own stock in it. As of 2024-06-30, the company held over 9.81 million shares (or 13.3274% of all shares), a total value of $25.51 million in shares.
The next largest institutional holding, with 5.56 million shares, is of VR ADVISER, LLC’s that is approximately 7.5468% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $14.44 million.
